Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation.
Abstract
Variations in cord blood manufacturing and administration are common, and the optimal
practice is not known. We compared processing and banking practices at 16 public cord
blood banks (CBB) in the United States and assessed transplantation outcomes on 530
single umbilical cord blood (UCB) myeloablative transplantations for hematologic malignancies
facilitated by these banks. UCB banking practices were separated into 3 mutually exclusive
groups based on whether processing was automated or manual, units were plasma and
red blood cell reduced, or buffy coat production method or plasma reduced. Compared
with the automated processing system for units, the day 28 neutrophil recovery was
significantly lower after transplantation of units that were manually processed and
plasma reduced (red cell replete) (odds ratio, .19; P = .001) or plasma and red cell
reduced (odds ratio, .54; P = .05). Day 100 survival did not differ by CBB. However,
day 100 survival was better with units that were thawed with the dextran-albumin wash
method compared with the "no wash" or "dilution only" techniques (odds ratio, 1.82;
P = .04). In conclusion, CBB processing has no significant effect on early (day 100)
survival despite differences in kinetics of neutrophil recovery.
Type
Journal articleSubject
Hematopoietic Stem CellsHumans
Transplantation Conditioning
Cord Blood Stem Cell Transplantation
Adolescent
Adult
Child
Child, Preschool
Female
Male
Allografts
Permalink
https://hdl.handle.net/10161/24651Published Version (Please cite this version)
10.1016/j.bbmt.2014.12.017Publication Info
Ballen, Karen K; Logan, Brent R; Laughlin, Mary J; He, Wensheng; Ambruso, Daniel R;
Armitage, Susan E; ... Eapen, Mary (2015). Effect of cord blood processing on transplantation outcomes after single myeloablative
umbilical cord blood transplantation. Biology of blood and marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation, 21(4). pp. 688-695. 10.1016/j.bbmt.2014.12.017. Retrieved from https://hdl.handle.net/10161/24651.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Joanne Kurtzberg
Jerome S. Harris Distinguished Professor of Pediatrics
Dr. Kurtzberg is an internationally renowned expert in pediatric hematology/oncology,
pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation,
and novel applications of cord blood and birthing tissues in the emerging fields of
cellular therapies and regenerative medicine. Dr. Kurtzberg serves as the Director
of the Marcus Center for Cellular Cures (MC3), Director of the Pediatric Transplant
and Cellular Therapy Program, Director of the Carolina

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info